Physiologically‐Based Pharmacokinetic‐Led Guidance for Patients With Cystic Fibrosis Taking Elexacaftor‐Tezacaftor‐Ivacaftor With Nirmatrelvir‐Ritonavir for the Treatment of COVID‐19

Cystic fibrosis transmembrane conductance regulator (CFTR) modulating therapies, including elexacaftor‐tezacaftor‐ivacaftor, are primarily eliminated through cytochrome P450 (CYP) 3A–mediated metabolism. This creates a therapeutic challenge to the treatment of coronavirus disease 2019 (COVID‐19) wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, Eunjin, Almond, Lisa M., Chung, Peter S., Rao, Adupa P., Beringer, Paul M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9087007/
https://www.ncbi.nlm.nih.gov/pubmed/35292968
http://dx.doi.org/10.1002/cpt.2585

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9087007/
https://www.ncbi.nlm.nih.gov/pubmed/35292968
http://dx.doi.org/10.1002/cpt.2585

Ejemplares similares